All
- All
- Articles
- Calendar
- Compliance
- Newsletter
- Position Statements
- Press Release
- Regulatory
- Uncategorized
FDA Issues FY23 Drug Safety Priorities Report
In February 2024, FDA's Center for Drug Evaluation and Research (CDER) published its ninth yearly report describing key safety programs and activities, and illustrating the...
Meet AAHP’s Newest Board Member
Brenda Van Goethem, Director of Regulatory Compliance & Change Management for Nature's Way, is the newest member of AAHP's Board of Directors. Elections for two-year...
FDA Warnings: Mistakes to Avoid
What Is Your Company Paying Attention To? And what is the FDA paying attention to? In a recent 30-day period, FDA sent 33 warning letters...
The Homeopathic Pharmacopoeia of the United States
By Mark Land, MS, RAC-US, AAHP President The Homeopathic Pharmacopoeia of the United States (HPUS) is the legal basis for marketing homeopathic drug products in...
The HPCUS Response to Current Challenges
By William Shevin, MD, DHt, HPCUS President After one of my patients with complex problems that defied even expert management by conventional means was dramatically...
Remote Regulatory Assessments
Remote Regulatory Assessments By Alvin J. Lorman, AAHP Counsel COVID-19 changed the way most people and most organizations operated. Like working from home, some of...
Improving Your Environmental Reputation
By Alissa Gould, Boiron USA, Director of Communications It's easy to argue that homeopathic manufacturing companies are ecological. Afterall, a small amount of resources from...
